Biotech Insider Buying: Synageva BioPharma Corp. (NASDAQ:GEVA), TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), CorMedix (NYSEMKT: CRMD)

Director Julian Baker acquired 1,000,000 shares of Synageva BioPharma Corp. (NASDAQ:GEVA) stock in a transaction that occurred on Wednesday, January 7th. The shares were purchased at an average cost of $94.19 per share, for a total transaction of $94,190,000.00. On Tuesday shares of Synageva BioPharma Corp. (NASDAQ:GEVA) closed at $109.83. Company’s sales growth for last 5 years was -7.30%

TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) CEO J Kevin Buchi purchased 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were purchased at an average cost of $5.04 per share, with a total value of $25,200.00. Following the completion of the purchase, the chief executive officer now directly owns 325,714 shares in the company, valued at approximately $1,641,598.56. On last trading day TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) moved up 1.80% to close at $6.21. Its volatility for the week is 8.97% while volatility for the month is 9.66%. TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) monthly performance is 2.31%.

VP, Gen. Counsel & Secretary of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Berkman Charles S had purchased shares worth of $5,699 in a transaction dated on December 31, 2014. A total of 126 shares were purchased at a price of $45.23 per share. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has 2.20% insider ownership while its institutional ownership stands at 94.10%. In last trading activity company’s stock closed at $52.04.

Analysts at Roth Capital set a $2.50 price target on shares of CorMedix (NASDAQ:CRMD) stock in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock. Roth Capital’s price target would indicate a potential upside of 67.79% from the company’s current price. On last trading day CorMedix, Inc. (NYSEMKT: CRMD) moved up 4.74% to close at $1.99. Its volatility for the week is 8.92% while volatility for the month is 8.08%. CRMD’s EPS growth for past 5 years was 4.10%. CorMedix, Inc. (NYSEMKT: CRMD) monthly performance is 39.16%.

Leave a Reply

Your email address will not be published. Required fields are marked *

*